FDA considers reclassification of hydrocodone-containing drugs

01/24/2013 | HealthDay News

An FDA panel was set to this week to consider reclassifying hydrocodone-containing products from Schedule III to Schedule II drugs. "Even if we change hydrocodone-containing products from Schedule III to Schedule II, it in no way jeopardizes access. What this means is that patients who might be able to go to their doctor every six months would now have to see their doctor every three months [to get a prescription]," said Dr. Andrew Kolodny, president of Physicians for Responsible Opioid Prescribing.

View Full Article in:

HealthDay News

Published in Briefs: